The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items

Load more

Select Page

Our Virus-Like Particles

The Native Antigen Company offers a range of recombinant virus-like particles for use in a variety of applications, including the development of in vitro diagnostic assays and vaccines.

Our Virus-Like Particles

Virus-like particles (VLPs) comprise the structural proteins of a viral particle, but don’t contain genomic material, making them non-infectious, while presenting all of the structural epitopes of a native virus. Because of these properties, VLPs have been increasingly used in diagnostic and vaccine R&D in recent years.

The Native Antigen Company has developed a range of over 20 virus-like particles. Produced from our VirtuE™ (HEK293) and insect-baculo expression systems, our VLPs are non-infectious and safe to use, while displaying native-like epitopes and glycosylation patterns. A study by Metz and colleagues, for example, showed that our VirtuE™-expressed dengue VLPs exhibit comparable epitopes to native viral particles.

Our VLPs are suitable for a wide range of applications, including the development of in vitro diagnostic assays and vaccines. The highly repetitive structural patterns presented by VLPs also makes them ideal antigens for raising high-avidity antibodies.

For more information on our VLP products, click the icons below:

Need More Information?

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below.

1 + 12 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

by | 2nd November 2022 | COVID-19 | 0 Comments

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...
Read More

The Role of Serology in Tracking COVID-19 Mutations

by | 27th August 2021 | COVID-19, Disease trends, Immunoassays, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...
Read More

Preparing for Disease Y: A Better Serological Toolbox

by | 26th July 2021 | COVID-19, Disease trends, Immunoassays, Neglected Tropical Diseases, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...
Read More

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

by | 3rd June 2021 | Coronaviruses, COVID-19, Disease trends | 0 Comments

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...
Read More

Making Sense of the SARS-CoV-2 Spike Mutations

by | 25th March 2021 | Coronaviruses, COVID-19, Disease insight, Disease trends, Immunoassays, New products, Research, Vaccines | 0 Comments

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...
Read More

D614G: Putting the Mutation in Perspective

by | 10th November 2020 | Coronaviruses, COVID-19, Disease insight, Disease trends, New products, Research | 0 Comments

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...
Read More

The Endemic Coronaviruses and What They Might Tell us About COVID-19

by | 29th July 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...
Read More

Q&A: An Insight Into COVID-19 Serology

by | 8th July 2020 | Coronaviruses, COVID-19, Immunoassays, Research | 0 Comments

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...
Read More

A Q&A with David Flavell of Leukaemia Busters

by | 20th May 2020 | Cancer, COVID-19, Disease insight, Research, Toxins | 0 Comments

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...
Read More

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

by | 4th May 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, Vaccines | 0 Comments

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...
Read More

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

by | 15th April 2020 | Coronaviruses, COVID-19, Immunoassays, Research, Vaccines | 0 Comments

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...
Read More

An Early Look at Vaccines for COVID-19

by | 14th April 2020 | Coronaviruses, COVID-19, Vaccines | 0 Comments

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...
Read More

Why We Need Antigen and Antibody Tests for COVID-19

by | 24th March 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...
Read More

Novel Coronavirus Antigens Now Available

by | 11th February 2020 | Coronaviruses, Disease insight, New products | 0 Comments

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...
Read More

Coronaviruses: The Next Disease X?

by | 5th November 2019 | Coronaviruses, Disease insight, New products | 0 Comments

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...
Read More